Latent autoimmune diabetes in adults

Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Retrieved on: 
Friday, June 17, 2022

SEATTLE, June 17, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, presented data showing survival of transplanted allogeneic, hypoimmune cells of several different types in a variety of locations in non-human primates (NHPs). The transplanted cells were induced pluripotent stem cell (iPSC)-derived cardiomyocytes, retinal pigment epithelium (RPE) cells, and islet cells, which were engineered to include Sana’s hypoimmune gene modifications that enable immune evasion. Data were presented by Sonja Schrepfer, M.D., Ph.D., Head of Hypoimmune Platform at Sana, during sessions at the International Society for Stem Cell Research (ISSCR) 2022 Annual Meeting taking place from Wednesday, June 15 through Sunday, June 19 in San Francisco.

Key Points: 
  • Transplanting cells or tissues from a donor to a different recipient currently requires intense immunosuppression to prevent rejection of the transplant.
  • Sanas HIP platform goal is to eliminate the need for immunosuppression by cloaking cells from immune recognition.
  • These changes alone make cells susceptible to innate immune cell killing, in particular by natural killer (NK) cells.
  • In this study, allogeneic primary pancreatic islet cells were HIP edited and transplanted intramuscularly into a healthy NHP without immunosuppression (n=1) as proof-of-concept.

NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

Retrieved on: 
Tuesday, May 10, 2022

The $600,000 grant, funded by JDRF to Yale, is a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).

Key Points: 
  • The $600,000 grant, funded by JDRF to Yale, is a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D).
  • The JDRF award will fund efforts to investigate the use of NexImmunes AIM nanoparticles in combination with a murine surrogate of teplizumab.
  • The identification of combination therapies for T1D is a critical piece of the JDRF strategy for accelerating the advancement of cures.
  • To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception.

United States Diabetic Food Markets, 2016-2020 & 2021-2026 - Focus on Baked Products, Beverages, Confectionery, Ice-Cream, Breakfast Cereals, & Dairy Products - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 6, 2022

The "United States Diabetic Food Market, By Product Type (Baked Products For Diabetics, Beverages For Diabetics, Confectionery For Diabetics, Ice Cream For Diabetics, Others), By Distribution Channel, By End Users, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Diabetic Food Market, By Product Type (Baked Products For Diabetics, Beverages For Diabetics, Confectionery For Diabetics, Ice Cream For Diabetics, Others), By Distribution Channel, By End Users, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • Major factors contributing to the growth in demand for diabetic food in the country include increasing awareness pertaining to diabetes.
  • Other major factors like increasing cases of obesity and diabetes owing to a lack of physical activity and sedentary lifestyle choices are projected to drive the United States diabetic food market through 2026.
  • Based on product type, the market can be fragmented into baked products for diabetics, beverages for diabetics, confectionery for diabetics, ice cream for diabetics, dairy products for diabetics and breakfast cereals for diabetics.

NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes

Retrieved on: 
Monday, August 9, 2021

The collaboration will focus on the use of NexImmunes direct injection, artificial antigen presenting cells (AIM INJ) with regards to the regulation of autoimmune diabetes (Type 1 diabetes).

Key Points: 
  • The collaboration will focus on the use of NexImmunes direct injection, artificial antigen presenting cells (AIM INJ) with regards to the regulation of autoimmune diabetes (Type 1 diabetes).
  • Dr. Kevan Herold, Deputy Director of Yale Center for Clinical Investigation and Co-Director of the Yale Diabetes Center will be the principal investigator.
  • Working with NexImmune allows us to explore a very compelling technology to impact this life-long and difficult to control disease, stated Dr. Herold.
  • The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response.

Diabetes Shown As Strongest Indicator Of Covid-19 Severity In Japanese Patients

Retrieved on: 
Friday, June 25, 2021

Results of the retrospective analysis were presented at the virtual 81st Scientific Sessions of the American Diabetes Association (ADA).

Key Points: 
  • Results of the retrospective analysis were presented at the virtual 81st Scientific Sessions of the American Diabetes Association (ADA).
  • A retrospective analysis in type 2 diabetes patients compared with a control was conducted.
  • Of the total 102 patients, 49% were type 2 diabetes patients.
  • Findings show that 88% of patients moving from the moderate to the severe classification had type 2 diabetes.

DGAP-News: Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes

Retrieved on: 
Wednesday, February 3, 2021

IMCY-0098, the most advanced ImotopeTM in development, is designed to halt the progression of diabetes by stopping the body's immune system from attacking beta-cells.

Key Points: 
  • IMCY-0098, the most advanced ImotopeTM in development, is designed to halt the progression of diabetes by stopping the body's immune system from attacking beta-cells.
  • The IMPACT Study is a multicenter, randomized, double-blind, placebo-controlled study in newly diagnosed T1D patients.
  • Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes(TM) for the treatment of several autoimmune diseases.
  • In most cases, the onset of T1D occurs in children and adolescents, but it can also affect adults.

Brawijaya University develops GAD65 Rapid Test Diabetes Screening Kit

Retrieved on: 
Wednesday, November 25, 2020

Malang, East Java, Indonesia, Nov 25, 2020 - (ACN Newswire) - Brawijaya University (UB) in Malang, East Java has developed an initial screening kit for diabetes.

Key Points: 
  • Malang, East Java, Indonesia, Nov 25, 2020 - (ACN Newswire) - Brawijaya University (UB) in Malang, East Java has developed an initial screening kit for diabetes.
  • The Bioscience Rapid Test GAD65, developed by aresearch team led by Prof. Dr. Aulanni'am, drh, DES, is ready for commercialization and use in early screening for Type I Diabetes Mellitus, before measures and treatment are determined.
  • The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults (LADA).
  • The Bioscience Rapid Test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya University and state-owned pharmaceutical company PT Bio Farma (Persero).

Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D)

Retrieved on: 
Thursday, October 1, 2020

RED BANK, N.J., Oct. 1, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national effort to redefine patient care in type 1 diabetes (T1D) with two complementary disease state and screening education campaigns. "

Key Points: 
  • RED BANK, N.J., Oct. 1, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national effort to redefine patient care in type 1 diabetes (T1D) with two complementary disease state and screening education campaigns. "
  • By getting screened for specific autoantibodies through a blood test, early-stage disease can be confirmed before any signs or symptoms appear.
  • Both campaigns focus on the need to screen patients at greater risk due to having a family member(s) with T1D.
  • Both are essential to redefining what patient care looks like for this chronic, life-altering, and life-threatening disease."

Defymed: Towards a Physiological Treatment for Type 1 Diabetes

Retrieved on: 
Tuesday, May 5, 2020

Insulin-dependent diabetes, known as Type 1 diabetes, is an autoimmune disease caused by the destruction of cells in the pancreas, causing the patient the inability to secrete insulin.

Key Points: 
  • Insulin-dependent diabetes, known as Type 1 diabetes, is an autoimmune disease caused by the destruction of cells in the pancreas, causing the patient the inability to secrete insulin.
  • Defymed initially focused on the application for the treatment of Type 1 diabetes.
  • The first product designed was MailPan, an implantable bioartificial pancreas created to reestablish normal insulin production in Type 1 diabetes patients.
  • Today, Defymed looks to apply its skills for the treatment of other pathologies such as cancer, hemophilia, and obesity.

Tiziana Life Science reports Independent Third Party Article in New England Journal of Medicine on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes

Retrieved on: 
Monday, July 1, 2019

The published results from a Phase 2 trial of Teplizumab, a mouse derived anti-CD3 mAb delivered intravenously, evaluated 76 patients who had relatives with Type 1 diabetes.

Key Points: 
  • The published results from a Phase 2 trial of Teplizumab, a mouse derived anti-CD3 mAb delivered intravenously, evaluated 76 patients who had relatives with Type 1 diabetes.
  • At 6 month intervals, the study tested subjects for the onset of Type 1 diabetes.
  • Teplizumab was found to significantly slow progression to clinical Type 1 diabetes, with a median delay in the diagnosis of diabetes of 2 years.
  • Children and adults at high risk of developing Type 1 diabetes may benefit from safe and effective prophylactic use of anti-CD3 mAbs.